Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9867
Title: | Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) | Authors: | Piessevaux, H. BUYSE, Marc De Roock, W. Prenen, H. Schlichting, M. Van Cutsem, E. Tejpar, S. |
Issue Date: | 2009 | Publisher: | OXFORD UNIV PRESS | Source: | ANNALS OF ONCOLOGY, 20(8). p. 1375-1382 | Abstract: | Patients and methods: Of the 329 patients, 289 had a measurement both at baseline and week 6. Tumor shrinkage was expressed as a relative decrease compared with baseline and categorized according to a previously reported cut-off value (similar to 10%) or used as a continuous variable. Results: Median time to progression (TTP) was 6.1 [95% confidence interval (CI) 5.1-7.2] versus 1.5 months (95% CI 1.4-1.7) in patients with [99 patients (34.3%)] or without [190 patients (65.7%)] tumor shrinkage, respectively, at week 6 [hazard ratio (HR) 0.23 (95% CI 0.17-0.32)]. The median overall survival (OS) was 13.7 (CI NA) versus 6.9 months (95% CI 6.1-7.7) [HR 0.21 (95% CI 0.14-0.32)], respectively. In a multivariate model, early tumor decrease outperformed skin toxicity as a predictor of long-term outcome. Conclusions: Tumor shrinkage at 6 weeks is a strong predictor of TTP and OS in cmCRC patients treated with cetuximab with or without irinotecan. This suggests early tumor shrinkage is the hallmark of efficacy of cetuximab and reliably identifies the subpopulation that is sensitive to the drug. Early tumor shrinkage can be used as a marker of efficacy in clinical practice, as such or in combination. | Notes: | [De Roock, W.; Prenen, H.; Van Cutsem, E.; Tejpar, S.] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Piessevaux, H.] Univ Catholique Louvain, Serv Gastroenterol, Clin Univ St Luc, B-1200 Brussels, Belgium. [Buyse, M.] Int Inst Drug Dev, Louvain, Belgium. [Buyse, M.] Univ Hasselt, Ctr Stat, Diepenbeek, Belgium. [Schlichting, M.] Merck KGaA, Darmstadt, Germany. | Keywords: | cetuximab; metastatic colorectal cancer; tumor measurements | Document URI: | http://hdl.handle.net/1942/9867 | ISSN: | 0923-7534 | e-ISSN: | 1569-8041 | DOI: | 10.1093/annonc/mdp011 | ISI #: | 000268806700011 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2010 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
57
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
66
checked on Apr 14, 2024
Page view(s)
90
checked on May 23, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.